clinical trials bound

Houston biotech company gets green light from FDA to test coronavirus-fighting drug

Pulmotect is headed to clinical trials to verify how its drug fights against COVID-19. Getty Images

Houston biotech company Pulmotect Inc. has embarked on two clinical drug trials that could create weapons for the battle against the novel coronavirus.

Pulmotect gained permission from the U.S. Food and Drug Administration to test its inhaled drug, PUL-042, as a way to prevent coronavirus infections and to slow the early progression of COVID-19, the potentially fatal disease caused by the novel coronavirus. Pulmotect developed PUL-042 to activate the lungs' front-line defense against respiratory infections, and now it's being enlisted in the race to devise coronavirus treatments and cures.

"We have demonstrated PUL-042's unique ability to stimulate the immune system in the lungs to protect against a wide range of pathogens in multiple animal models," Dr. Colin Broom, CEO of Pulmotect, says in a May 7 release. "Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of [the coronavirus] and future emerging pathogens, and protecting vulnerable populations."

Unlike a vaccine, which typically takes 10 to 15 years to bring to the market, PUL-042 promises much faster deployment as scientists and health care workers wage war against COVID-19.

Each of the two clinical trials, both in the second phase, is being conducted at 10 sites across the U.S., including locations in Houston. In all, 20 sites are participating. Money for the trials came from the company's recently completed $12 million round of series B funding.

Pulmotect's partner in the trials is Covington, Kentucky-based CTI Clinical Trial and Consulting Services Inc. PARI Respiratory Equipment Inc., whose North American headquarters is in Midlothian, Virginia, is supplying medical equipment known as nebulizers to administer Pulmotect's inhaled drug.

"Both clinical trials are placebo-controlled to objectively evaluate safety and efficacy," Broom says in a May 5 release.

"In the first study, up to four doses of PUL-042 or placebo will be administered to 200 subjects by inhalation over a 10-day period to evaluate the prevention of infection and reduction in severity of COVID-19. In the second study, 100 patients with early symptoms of COVID-19 will receive the treatment administered up to three times over six days. In both trials, subjects will be followed up for 28 days to assess the effectiveness and tolerability of PUL-042."

Previous experiments conducted by Pulmotect indicate PUL-042 effectively protects mice against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which are caused by coronaviruses that differ from the COVID-19 virus. Researchers performed those tests at the University of Texas Medical Branch at Galveston.

PUL-042 initially was developed to fight respiratory problems in cancer patients undergoing chemotherapy, which weakens the immune system. But the drug offers the potential to prevent or treat an array of respiratory infections caused by viruses, bacteria, or fungi.

"We have always considered PUL-042 to have the potential for the prevention and treatment of emerging epidemics and pandemics like the one we currently face," Broom says.

A separate trial of PUL-042 is underway in London. There, the drug is being tested on patients with chronic obstructive pulmonary disease (COPD) who are susceptible to lung infections. COPD is an inflammatory disease that blocks airflow from the lungs. People with COPD face a heightened risk of conditions like heart disease and lung cancer, the Mayo Clinic says.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's PUL-042, which holds patents in 10 countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which fosters early stage companies in the life sciences sector.

Trending News

Building Houston

 
 

Graduates are tossing their hats into an uncertain world right now. Photo by skynesher/Getty Images

This year's college graduates are entering a real world that's more unreal than any we've seen in our lifetimes. And they're facing a world with uncertain prospects.

Against that jarring backdrop, the Apartment List website developed a ranking of the top U.S. metro areas for college graduates, and Houston sits in the middle of the pack. The Bayou City ranks 26th among the country's 50 largest metro areas.

The ranking, published May 13, takes into account six data points:

  • Average wages among recent college graduates
  • March 2020 unemployment rate
  • Rental costs for recent college graduates
  • Share of adult population with a college degree
  • Share of recent college graduates working in remote-friendly occupations
  • Share of workforce in high-risk industries

Houston fares well in terms of average wages among recent college graduates ($46,681) and college graduates working in remote-friendly occupations (73 percent), but doesn't fare as well for the share of adults with a college degree (31 percent) and the share of full-time workers in high-risk industries (13 percent).

Austin appears at No. 6 on the list, with Dallas-Fort Worth at 21 and San Antonio at No. 43. Apartment List says Austin's economic scores "are well-rounded across the board," but the metro area stands out for its high share of college-educated adults (43 percent) and high share of college graduates working in remote-friendly occupations (77 percent).

"Each of the nation's five largest metropolitan areas — New York, Los Angeles, Chicago, Dallas, and Houston — failed to break the Top 10," Apartment List notes. "The Class of 2020 is better off looking into smaller regions that strike a healthier balance between affordability and economic opportunity."

San Jose, California, the epicenter of Silicon Valley, tops the ranking, followed by San Francisco; Washington, D.C.; Boston; and Milwaukee.

Ranked last is Las Vegas, preceded by Riverside-San Bernardino, California; New Orleans; Miami; and Orlando, Florida.

------

This article originally ran on CultureMap.

Trending News